Latest Breaking News On - Peter mohr - Page 1 : vimarsana.com

Rick Collins takes on the presidency role at MCUE Goannas | The Daily Advertiser

LGBTQ landmark in Rochester turns 50

Rochester's Bachelor Forum, oldest gay bar, celebrates golden anniversary

Rochester's oldest gay bar, The Bachelor Forum, celebrated its 50th anniversary on Saturday.

Ash Reynoldson has topped off a remarkable season by winning her third straight best and fairest at the Goannas | The Daily Advertiser

Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023

First presentation of results from CheckMate -901 show survival benefit with Opdivo + chemotherapy in the first-line treatment of patients with unresectable or metastatic urothelial carcinoma who...

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Tre

Approval based on results from the Phase 3 CheckMate -76K trial in patients with stage IIB or IIC melanoma, in which Opdivo reduced the risk of recurrence or death by 58% versus placeboOpdivo is the only PD-1 inhibitor that is indicated as an adjuvant treatment for patients within stages IIB, IIC, III, as well as st...

Bristol Myers Squibb's Opdivo approved by EC for expanded melanoma use

Bristol-Myers Squibb (BMY) Receives European Commission Approval for Opdivo as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

22.08.2023 - Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) as a monotherapy for the adjuvant treatment of adults and adolescents 12 years of age and older with stage IIB or IIC melanoma who ...

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma   -Today at 04:19 pm

Approval based on results from the Phase 3 CheckMate -76K trial in patients with stage IIB or IIC melanoma, in which Opdivo reduced the risk of recurrence or death by 58% versus placebo Opdivo is...